# clm_0598850A1A59

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: quarterly_net_income  
value: 968,400,000 United States dollar  
valid_from: 2023-06-30  
valid_to: 2023-09-30  
published: 2023-08-03  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_0089CAC97396  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals quarterly net income: 968,400,000 United States dollar", as of 2023-06-30 (until 2023-09-30). Claim clm_0598850A1A59, https://asof.is/claim/clm_0598850A1A59, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-03  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000180422023000023/0001804220-23-000023-index.htm (primary, SEC EDGAR 10-Q Q2 FY2023, published 2023-08-03)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_net_income | 817,800,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_0598850A1A59](/claim/clm_0598850A1A59.md) | [clm_802196BED548](/claim/clm_802196BED548.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.